TENERGY: multicenter phase II study of Atezolizumab monotherapy following definitive Chemoradiotherapy with 5-FU plus Cisplatin in patients with unresectable locally advanced esophageal squamous cell carcinoma

Hideaki Bando¹, Daisuke Kotani², Takahiro Tsushima³, Hiroki Hara⁴, Shigenori Kadowaki¹, Ken Kato⁵, Keisho Chin⁶, Kensei Yamaguchi⁶, Shun-ichiro Kageyama⁷, Hidehiro Hojo⁷, Masaki Nakamura⁷, Hidenobu Tachibana⁷, Masashi Wakabayashi⁸, Miki Fukutani⁸, Yosuke Togashi⁹, Nozomu Fuse⁸, Hiroyoshi Nishikawa⁹ and Takashi Kojima²*

Abstract

Background: The standard treatment for patients with unresectable locally advanced esophageal squamous cell carcinoma (ESCC) is definitive chemoradiotherapy (CRT) using 5-FU plus cisplatin. However, complete response (CR) rates are low at 11–25%, resulting in 9–10 months of median overall survival (OS). An improved therapeutic efficacy by combining immunotherapy with radiation has been reported in patients with locally advanced non-small cell lung cancer. The results using ESCC cell lines suggest sequential treatment with anti-PD-L1 agents soon after completion of CRT is the most effective combination.

(Continued on next page)
Background
Carcinoma of the esophagus is an extremely devastating disease, especially when the disease invades adjacent structures such as aorta, vertebral bodies, or trachea (T4b), and becomes unresectable. According to the Comprehensive Registry of Esophageal Cancer in Japan, the incidence of T4b esophageal cancer accounts for approximately 6.7% of all patients with esophageal cancer (approximately 1500 patients per year) [1]. The standard treatment for this population is definitive chemoradiotherapy (CRT) using 5-FU plus cisplatin. However, complete response (CR) rates are low at 11 to 25%, resulting in 9 to 10 months of median overall survival (OS) [2–4]. Although new strategies have been investigated [4], the treatment regimens have not changed since 1990s.

Immunotherapy with immune checkpoint inhibitors (ICIs) has revolutionized the treatment of advanced cancers, including that of esophageal cancer. Pembrolizumab, an anti-programmed death 1 (PD-1) antibody, significantly improved OS in patients with programmed death ligand 1 (PD-L1) combined positive score (CPS) ≥10 metastatic esophageal cancer [5]. Subgroup analyses indicated higher efficacies of pembrolizumab for patients with esophageal squamous cell carcinoma (ESCC) than those for patients with adenocarcinoma, and the Food and Drug Administration (FDA) approved pembrolizumab for patients with metastatic ESCC whose tumors express PD-L1 CPS ≥10 after ≥1 prior line of systemic therapy. Subsequently, nivolumab, another anti-PD-1 antibody, showed significant OS improvement in patients with metastatic ESCC after ≥1 prior line of systemic therapy (regardless of PD-L1 status) [6].

ICIs combined with ionizing radiation are promising approaches due to their efficacies. Mechanisms facilitating the action of ICIs by radiation include increased tumor antigen release, activation of innate immune pathway, increased T-cell infiltration, augmented antigen presentation, and modulation of immunosuppressive cells [7, 8]. Indeed, in vivo models, sequential combination of an anti-PD-1 antibody and radiation increased the proportion of tumor antigen complexes and major histocompatibility complex (MHC) molecules, enhanced lymph node cross-presentation, and increased T-cell tumor infiltration [9]. The polyclonal T-cell response also mediated out-of-field (abscopal) effects following local radiotherapy [10]. An abscopal effect from the combination of radiation and immunotherapy has also been reported in cases with different cancer types [11]. Phase I trials showed a 10–13.5% response rate for liver or lung metastases outside the radiation field [12, 13]; thus, similar efficacies may be expected for micro metastatic lesions in patients with locally advanced cancer.

According to other studies, chemotherapy and radiotherapy may mediate the release of interferon gamma (IFN-γ) produced by CD8+ T cells resulting in PD-L1 upregulations in various tumor cells [8, 14]. Our preliminary studies using both ESCC cell lines and a radiation irradiation device used in the clinical practice also reported that 60 Gy of radiation upregulated only the expression of PD-L1 and MHC Class I without affecting the expression of PD-L2 (data not shown). As lymphocytes are radiation sensitive, we hypothesized that the sequential treatment with anti-PD-L1 agents soon after completion of CRT would enhance the treatment efficacies.

Methods: TENERGY trial is a multicenter, phase II, proof-of-concept study to assess the efficacy and safety of atezolizumab following definitive CRT in patients with locally advanced ESCC. The main inclusion criteria are unresectable locally advanced ESCC without distant metastasis, completion of 60 Gy of radiation plus two concomitant cycles of chemotherapy (cisplatin 70 mg/m² on day 1 and 5-FU 700 mg/m² on days 1–4, every 28 days), and adequate organ function. Within 6 weeks after CRT, participants will start taking 1200 mg of atezolizumab every three weeks and continue until 12 months or disease progression. The primary endpoint is the confirmed CR rate by the investigator’s assessment. Secondary endpoints include overall response rate, progression-free survival (PFS), OS, adverse events, and confirmed CR rate by central assessment. We will enroll 50 patients (40 with primary locally advanced ESCC and 10 with postoperative locoregionally recurrent ESCC). We will obtain biopsies from the primary site and will collect blood at 3 time points (before CRT, after CRT, and four weeks after the start of atezolizumab) for an exploratory biomarker study. We will analyze the phenotype of immune-competent cells, neoantigens, tumor mutational burden, PD-L1 status, and Human Leukocyte Antigen haplotyping.

Discussion: The synergistic efficacies of the sequential combination of CRT and atezolizumab should improve the CR rate, resulting in survival improvement for patients with unresectable locally advanced ESCC. Because CRT is a standard treatment option for patients with early stage to locally advanced ESCC, the sequential combination of CRT and atezolizumab has the potential to change the standard ESCC treatments.

Trial registration: UMIN000034373, 10/04/2018 and EPOC1802.

Keywords: Unresectable locally advanced, Esophageal squamous cell carcinoma, Chemoradiotherapy, Atezolizumab
Among patients with unresectable locally advanced non-small cell lung cancer, 12 months of the anti-PD-L1 antibody durvalumab following platinum-based CRT significantly improved both PFS and OS irrespective of PD-L1 expression before CRT [15, 16]. Durvalumab also had a favorable effect on the frequency of new metastases, including on the incidence of new brain metastases. The safety profile of durvalumab was consistent with those of other immunotherapy-related trials, and included a relatively high but acceptable radiation or ICI-induced pneumonitis rate.

Based on this information, we have planned a phase II proof-of-concept (POC) clinical trial to evaluate the safety and efficacy of the anti-PD-L1 antibody atezolizumab following definitive CRT in patients with unresectable locally advanced ESCC.

Methods/design
Study design and treatment
The TENERGY trial is a multicenter, phase II POC study to assess the safety and efficacy of a sequential combination therapy with atezolizumab following 5-FU plus cisplatin-based chemoradiotherapy (60 Gy/30 fractions without prophylactic irradiation) in patients with unresectable locally advanced ESCC without distant metastasis. This study consists of two parts: we will enroll patients with primary locally advanced ESCC into the primary locally advanced ESCC part, and patients with locoregionally recurrent ESCC after surgical resection into the postoperative locoregionally recurrent ESCC part (Fig. 1).

Table 1 shows the inclusion and exclusion criteria for both parts. We will provide the intervention treatment to patients who meet all the inclusion criteria and do not meet any of the exclusion criteria. Although the CRT is not included in the protocol therapy, both chemotherapy and radiation will be stringently qualified based on the quality assurance and quality control program. We will initiate the study intervention treatment within 6 weeks after CRT completion. Patients will receive 1200 mg of atezolizumab every three weeks until 12 months (maximum of 17 doses), disease progression, patient withdrawal, investigator’s decision, pregnancy, or unacceptable toxicities (whichever comes first).

We are conducting this study in accordance with the guidelines for Good Clinical Practice of the International Council on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, as well as with the ethical guidelines for medical and health research involving human subjects. All patients are required to sign written informed consents. We registered the study in the University Hospital Medical Information Network (Clinical trial information number: UMIN000034373).

![Fig. 1 Study design. The TENERGY trial consists of two parts. After completion of definitive chemoradiotherapy, patients with primary locally advanced esophageal squamous cell carcinoma (ESCC) will be enrolled into the primary locally advanced ESCC part (N = 40). Patients with locoregionally recurrent ESCC after surgical resection will be enrolled into the postoperative locoregionally recurrent ESCC part (N = 10).](image-url)
Table 1 Patient inclusion and exclusion criteria

Inclusion Criteria

1. Patients with histologically confirmed primary esophageal squamous cell carcinoma, adenosquamous carcinoma, or basaloid-squamous carcinoma.

2. Patients with primary lesion located in the thoracic esophagus based on the UICC TNM 7th edition classification, with invasion to cervical esophagus and/or abdominal esophagus who are eligible when definitive CRT is performed. Patients with secondary lesions that are curable by endoscopic resection are eligible.

3. Patients diagnosed as having an unresectable tumor by a pre-CRT CT scan as described below. Patients with esophageal perforation, esophagotracheal fistula, esophagomediastinal fistula, bleeding from arterial invasion, or respiratory stenosis are ineligible.

- The depth of the primary tumor is diagnosed as T4b (tumor invades other adjacent structures such as aorta, vertebral body, or trachea) according to the UICC TNM 7th edition and Japanese Classification of Esophageal Cancer The 11th Edition.
- Regional lymph nodes and/or supraclavicular lymph node have invaded adjacent structures other than esophagus.
- Patients without distant metastases other than supraclavicular lymph node by pre-CRT CT scan.
- Patients without prior esophageal cancer treatment except for endoscopic resection before CRT.
- Patients for whom the CRT described below has been performed and for whom the protocol treatment can be started within 42 days after CRT completion.
- Chemotherapy started at CDDP 70 mg/m² on day 1, 5-FU 700 mg/m² on days 1-4 and 2 times every 4 weeks. Second cycle dose reductions were allowed according to the toxicities.
- 60 Gy/30 fractions of radiotherapy performed without exceeding dose limitations to at-risk organs.
- Patients without esophageal perforation, esophagotracheal fistula, esophagomediastinal fistula, bleeding from arterial invasion, or respiratory stenosis when CRT is completed.

Inclusion Criteria (for the postoperative locoregionally recurrent ESCC part)

1. Patients with histologically confirmed esophageal squamous cell carcinoma, adenosquamous carcinoma, or basaloid-squamous carcinoma on surgical specimens.

2. Patients with local (mediastinum, anastomosis) or regional (regional lymph node) recurrences after curative surgery, whose recurrences are considered treated with definitive CRT.

3. Patients without distant metastases except those in supraclavicular lymph nodes by pre-CRT CT scan.

4. Patients treated with neoadjuvant chemotherapy 24 months or more before start-up of any definitive CRT.

5. Patients for whom the CRT described below has been performed and those for whom the protocol treatment can be started within 42 days after CRT completion.

- Chemotherapy started at CDDP 70 mg/m² on day 1, 5-FU 700 mg/m² on days 1-4 and 2 times every 4 weeks. Second cycle dose reductions were allowed according to the toxicities.
- 60 Gy/30 fractions of radiotherapy performed without exceeding dose limitations to at-risk organs.

- Patients without esophageal perforation, esophagotracheal fistula, esophagomediastinal fistula, bleeding from arterial invasion, or respiratory stenosis when CRT is completed.

Table 1 Patient inclusion and exclusion criteria (Continued)

Exclusion Criteria

1. Patients with active multiple primary cancers (synchronous multiple primary cancers and multiple cancers with a progression-free period of ≤3 years from the time of enrollment), carcinoma in situ or intramucosal carcinoma curable by local resection are not included in the definition of active multiple primary cancers.

2. Patients with active infection for which systemic treatments are needed.

3. Patients with past or concurrent inflammatory bowel disease.

4. Patients with past or concurrent pneumonitis or interstitial lung disease (ILD).

5. Patients with concurrent autoimmune disease or with past chronic or recurrent autoimmune disease.

6. Patients requiring treatment with systemic corticosteroids or immunosuppressants.

7. Patients with past or concurrent thyroid dysfunction (hyperthyroidism or hypothyroidism).

8. Patients with a history or finding of a cardiovascular risk:
   - Patients with a left ventricular ejection fraction below 50%.
   - Patients with clinically significant, poorly controlled arrhythmia.
   - Patients with acute coronary syndrome, coronary angioplasty, or stent placement within 6 months before enrollment.

9. Patients with poorly controlled diabetes mellitus.

10. Patients positive for HIV antibody, HBs antigen or HCV antibody.

11. Patients positive for HIV antibody, HBs antigen or HCV antibody.

12. Patients with a history or finding of a cardiovascular risk:
   - Patients with a left ventricular ejection fraction below 50%.
   - Patients with clinically significant, poorly controlled arrhythmia.
   - Patients with acute coronary syndrome, coronary angioplasty, or stent placement within 6 months before enrollment.

13. Patients with poorly controlled diabetes mellitus.

14. Patients positive for HIV antibody, HBs antigen or HCV antibody.

15. Patients with poorly controlled diabetes mellitus.

16. Patients positive for HIV antibody, HBs antigen or HCV antibody.

17. Patients with poorly controlled diabetes mellitus.

18. Patients positive for HIV antibody, HBs antigen or HCV antibody.

19. Patients with poorly controlled diabetes mellitus.

20. Patients positive for HIV antibody, HBs antigen or HCV antibody.

21. Patients with poorly controlled diabetes mellitus.

22. Patients positive for HIV antibody, HBs antigen or HCV antibody.

23. Patients with poorly controlled diabetes mellitus.

24. Patients positive for HIV antibody, HBs antigen or HCV antibody.

25. Patients with poorly controlled diabetes mellitus.

26. Patients positive for HIV antibody, HBs antigen or HCV antibody.

27. Patients with poorly controlled diabetes mellitus.

28. Patients positive for HIV antibody, HBs antigen or HCV antibody.

29. Patients with poorly controlled diabetes mellitus.

30. Patients positive for HIV antibody, HBs antigen or HCV antibody.

31. Patients with poorly controlled diabetes mellitus.

32. Patients positive for HIV antibody, HBs antigen or HCV antibody.

33. Patients with poorly controlled diabetes mellitus.

34. Patients positive for HIV antibody, HBs antigen or HCV antibody.

35. Patients with poorly controlled diabetes mellitus.

36. Patients positive for HIV antibody, HBs antigen or HCV antibody.

37. Patients with poorly controlled diabetes mellitus.

38. Patients positive for HIV antibody, HBs antigen or HCV antibody.

39. Patients with poorly controlled diabetes mellitus.

40. Patients positive for HIV antibody, HBs antigen or HCV antibody.

41. Patients with poorly controlled diabetes mellitus.

42. Patients positive for HIV antibody, HBs antigen or HCV antibody.

43. Patients with poorly controlled diabetes mellitus.

44. Patients positive for HIV antibody, HBs antigen or HCV antibody.

45. Patients with poorly controlled diabetes mellitus.

46. Patients positive for HIV antibody, HBs antigen or HCV antibody.

47. Patients with poorly controlled diabetes mellitus.

48. Patients positive for HIV antibody, HBs antigen or HCV antibody.

49. Patients with poorly controlled diabetes mellitus.

50. Patients positive for HIV antibody, HBs antigen or HCV antibody.

51. Patients with poorly controlled diabetes mellitus.

52. Patients positive for HIV antibody, HBs antigen or HCV antibody.

53. Patients with poorly controlled diabetes mellitus.

54. Patients positive for HIV antibody, HBs antigen or HCV antibody.

55. Patients with poorly controlled diabetes mellitus.

56. Patients positive for HIV antibody, HBs antigen or HCV antibody.

57. Patients with poorly controlled diabetes mellitus.

58. Patients positive for HIV antibody, HBs antigen or HCV antibody.

59. Patients with poorly controlled diabetes mellitus.

60. Patients positive for HIV antibody, HBs antigen or HCV antibody.

61. Patients with poorly controlled diabetes mellitus.

62. Patients positive for HIV antibody, HBs antigen or HCV antibody.

63. Patients with poorly controlled diabetes mellitus.

64. Patients positive for HIV antibody, HBs antigen or HCV antibody.

65. Patients with poorly controlled diabetes mellitus.

66. Patients positive for HIV antibody, HBs antigen or HCV antibody.

67. Patients with poorly controlled diabetes mellitus.

68. Patients positive for HIV antibody, HBs antigen or HCV antibody.

69. Patients with poorly controlled diabetes mellitus.

70. Patients positive for HIV antibody, HBs antigen or HCV antibody.

71. Patients with poorly controlled diabetes mellitus.

72. Patients positive for HIV antibody, HBs antigen or HCV antibody.

73. Patients with poorly controlled diabetes mellitus.

74. Patients positive for HIV antibody, HBs antigen or HCV antibody.

75. Patients with poorly controlled diabetes mellitus.

76. Patients positive for HIV antibody, HBs antigen or HCV antibody.

77. Patients with poorly controlled diabetes mellitus.

78. Patients positive for HIV antibody, HBs antigen or HCV antibody.

79. Patients with poorly controlled diabetes mellitus.

80. Patients positive for HIV antibody, HBs antigen or HCV antibody.

81. Patients with poorly controlled diabetes mellitus.

82. Patients positive for HIV antibody, HBs antigen or HCV antibody.

83. Patients with poorly controlled diabetes mellitus.

84. Patients positive for HIV antibody, HBs antigen or HCV antibody.

85. Patients with poorly controlled diabetes mellitus.

86. Patients positive for HIV antibody, HBs antigen or HCV antibody.

87. Patients with poorly controlled diabetes mellitus.

88. Patients positive for HIV antibody, HBs antigen or HCV antibody.

89. Patients with poorly controlled diabetes mellitus.

90. Patients positive for HIV antibody, HBs antigen or HCV antibody.
Target sample size and statistical analyses

The reported CR rates have ranged from 11 to 25%. In this study, we estimate a rate of 20% as the CR threshold. Therefore, we calculated the sample size of the primary locally advanced ESCC part at 38 with a CR of 40% deemed promising and one of 20% deemed unacceptable (one-sided α, 0.05; β, 0.2). Under this calculation, we are planning to include a maximum of 40 patients in the primary locally advanced ESCC part. We set the planned sample size of the postoperative locoregionally recurrent ESCC part at a maximum of 10 patients in an exploratory manner. We will calculate the confirmed CR by the investigator’s assessment and its 90% confidence interval using the exact binomial method. The results will be considered statistically significant with more than 13 confirmed CR cases in accordance with both the RECIST and the Japanese Classification of Esophageal Cancer in the primary locally advanced ESCC part (i.e., CR rate ≥ 34.2%). We will also determine the confirmed CR rate by central assessment, the ORR by the investigators’ assessment, the PFS, and the OS using appropriate statistical methods. Finally, we will also tabulate the incidence of AEs in the safety population.

Biomarker analyses and translational research

We will perform serial biopsies from the primary site and blood collections at 3 time points (before CRT, after CRT, and four weeks after the first atezolizumab dose). Using the collected samples, we will investigate biomarkers for efficacy or resistance to the sequential combination of CRT and atezolizumab. We will also analyze whole exome sequencing, neoantigens, microsatellite instability, tumor mutational burden, phenotype of immune-competent cells using both flow cytometry and immunohistochemistry, PD-L1 status, and Human Leukocyte Antigen haplotyping.

Discussion

The TENERGY trial is the first phase II POC study to evaluate the efficacy and safety of sequential combination therapy with 1 year of atezolizumab following definitive CRT in patients with unresectable locally advanced ESCC. The synergistic efficacies of CRT plus ICIs combination should improve the confirmed CR rate, resulting in a prolonged survival. If the combination significantly improves the confirmed CR rate, we will plan a confirmatory phase III trial. Also, as the incidence of T4b esophageal cancer is estimated approximately at 1500 patients per year in Japan, we expect the Japanese Accelerated Approval Program will allow for earlier approval of drugs that treat serious conditions, and that fill an unmet medical need.

Moreover, because CRT is one of the standard treatment options for patients with early stage to locally advanced ESCC, the application of sequential combinations of CRT plus ICIs should be potentially expandable to patients with all ESCC stages and the results of our trial may guide standard ESCC treatment modifications.
Acknowledgements

We would like to express special thanks to all participating patients, their families, and all participating investigators.

Authors’ contributions

All authors have read and approved the manuscript. Study concepts: HB, DK, NF, and TK; Study design: HB, DK, YT, NF, HN and TK; Data acquisition: HB, DK, TT, HH, SK, KK, KC, KY, SK, HH, MN, HT, MW, MF, YT, NF, HN, and TK; Quality control of data and algorithms: SK, HH, MN, HT, MF, and NF; Statistical analysis: MW; Manuscript preparation: HB, DK, NF, and TK; Manuscript editing: HB, DK, TT, HH, SK, KK, KC, KY, SK, HH, MN, HT, MW, MF, YT, NF, HN, and TK; Manuscript review: HB, DK, TT, HH, SK, KK, KC, KY, SK, HH, MN, HT, MW, MF, YT, NF, HN, and TK.

Funding

This investigator-initiated trial is supported by Japan Agency for Medical Research and Development (AMED) (Grant Number 18dk0106420h0001). Chugai Pharmaceutical provided the fund for translational research and the study drugs. Our study protocol was submitted to AMED and Chugai Pharmaceutical for peer-review and was approved. The funding bodies do not affect the design of the study, data collection, data analysis, interpretation of data, and writing the manuscript.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate

We are conducting this study in accordance with the guidelines for Good Clinical Practice of the International Council on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, as well as with the ethical guidelines for medical and health research involving human subjects. This study was approved by the ethics committees at each institution (National Cancer Center Institutional Review Board, Aichi Cancer Center Institutional Review Board, Saitama Cancer Center Review Board, Shizuoka Cancer Center Review Board, Cancer Institute Hospital of Japanese Foundation for Cancer Research Review Board). All patients are required to sign written informed consents.

Consent for publication

Not applicable.

Competing interests

HB reports research funding from AstraZeneca and Symex, and honoraria from Taiho. DK reports receiving honoraria from Takeda, Chugai, Lilly, Merck Biopharma, Taiho, and Symex. TT reports no competing interests. HH reports paid consulting or advisory roles for Chugai, Merck Biopharma, Ono and MSD; honoraria from Chugai, Taiho, Merck Biopharma, Yakult, Lilly, Takeda, Bristol-Myers Squibb, Sanofi, Ono and MSD; and research funding from Astellas, AstraZeneca, Merck Biopharma, Takeda, Boehringer Ingelheim, Lilly, Ono, Sumitomo Dainippon, Daiichi Sankyo, Taiho, Chugai, MSD, Pfizer, Incyte, Beligene, LSK BioPharma and Eisai. SK reports research funding from Taiho, Lilly, and Ono, and honoraria from Taio, Lilly, Ono, Bristol-Myers Squibb, Yakult, Chugai, Bayer, and Merck Biopharma. KK and KC reports no competing interests. KY, SK, and HH reports no competing interests. MN reports personal fees from MSD and AstraZeneca. HT, MW, and MF report no competing interests. YT reports honoraria from Ono, Bristol-Myers Squibb, Chugai, MSD, and AstraZeneca. NF and HN reports no competing interests. TK reports paid consulting or advisory roles for Bristol-Myers Squibb, honoraria from Oncolyx BioPharma, and research funding from Ono, MSD, Oncolyx BioPharma, Shionogi, Chugai and Astellas Amgen BioPharma.

Author details

1. Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan. 2. Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan. 3. Division of Gastrointestinal Oncology Chiba University Hospital, Chiba, Japan. 4. Department of Gastroenterology, Saitama Cancer Center, Saitama, Japan. 5. Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan. 6. Department of Gastroenterological Medicine, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan. 7. Division of Radiation Oncology and Particle Therapy, National Cancer Center Hospital East, Kashiwa, Japan. 8. Clinical Research Support Office, National Cancer Center Hospital East, Kashiwa, Japan. 9. Division of Cancer Immunology, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center Hospital East, Kashiwa, Japan.

Received: 10 January 2020 Accepted: 5 March 2020

References

1. Tachimori Y, Ozawa S, Numaiishi H, Iizhara R, Matakeba H, Muro K, et al. Comprehensive registry of esophageal cancer in Japan. 2012. Esophagus. 2019;16:241–5.
2. Ishida K, Ando N, Yamamoto S, Ide H, Shinozuka M. Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japanese esophageal oncology group (JEUG) Japan clinical oncology group trial (UCG0516). Jpn J Clin Oncol. 2004;34:615–9.
3. Ohtsu A, Boku N, Muro K, Chin K, Muto M, Yoshida S, et al. Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. J Clin Oncol. 1999;17:2915–21.
4. Shinozuka M, Ando N, Kato K, Iizhara K, Sato H, Tsuoba Y, et al. Randomized study of low-dose versus standard-dose chemoradiotherapy for resectable esophageal squamous cell carcinoma (COCG0704). Cancer Sci. 2015;106:407–12.
5. Kojima T, Muro K, Franceso E, Hsu CH, Mertwali T, Kim SB, et al. Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: phase III KEYNOTE-181 study. J Clin Oncol. 2019;37:2.
6. Kato K, Cho BC, Takahashi M, Okada M, Lin CY, Chin K, Kadowaki S, et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3); a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(11):1506–17.
7. Deng L, Liang H, Burnett B, Beckett M, Darga T, Weichselbaum RR, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest. 2014;124:687–95.
8. Dovedi SJ, Adlard AL, Lipowski-Bhalla G, McKenna C, Jones S, Cheadle EJ, et al. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Cancer Res. 2014;74:5458–68.
9. Sharabi AB, Nirschl CJ, Kochel CM, Nirschl TR, Francica BJ, Velarde E, et al. Stereotactic radiation therapy augments antigen-specific PD-1-mediated antitumor immune responses via cross-presentation of tumor antigen. Cancer Immunol. 2015;3:345–55.
10. Park SS, Dong H, Liu X, Harrington SM, Krico CJ, Grans MP, et al. PO-1.1 restrains radiotherapy-induced abscopal effect. Cancer Immunol Res. 2015;3:610–9.
11. Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitanov S, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 2012;366:925–31.
12. Tang C, Welsh JW, de Groot P, Massarelli E, Chang JY, Hess KR, et al. Ipilimumab with stereotactic ablative radiation therapy: phase I results and immunologic correlates from peripheral T cells. Clin Cancer Res. 2017;23:1388–96.
13. Luke JJ, Lemons JM, Karrson TG, Meletoki JM, Zha Y, AH Hallaj HA, et al. Safety and clinical activity of pembrolizumab and multistate stereotactic body radiotherapy in patients with advanced solid tumors. J Clin Oncol. 2018;36:1611–8.
14. Zhang P, Su DM, Liang M, Fu J. Chemoimmunologic agents induce programmed death-1–ligand 1 (PD-1–L1) surface expression in breast cancer cells and promote PD-1–L1-mediated cell apoptosis. Mol Immunol. 2008;45:1470–6.
15. Antonio S, Villegas A, Daniel D, Vocente D, Musiakian S, Hui R, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017;377:1919–29.
16. Antonio S, Villegas A, Daniel D, Vocente D, Musiakian S, Hui R, et al. Overall survival with Durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med. 2018;379:2542–50.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.